About RTX‑240 Clinical Trials

Participating in a clinical trial is a significant commitment.
We are grateful for the important contributions of the volunteers who take part in this important research.

About the RTX‑240
phase 1/2 clinical trial

This Phase 1/2 clinical trial is designed to establish whether RTX‑240 is safe, how much RTX‑240 needs to be given for it to be effective, and how often it should be given to be effective. The trial seeks to evaluate:

  • Any side effects associated with RTX‑240
  • Preliminary dose and schedule, meaning how much RTX‑240 needs to be given for it to be effective, and how often it should be given to be effective

All study participants
receive at no cost:

The study drug, study-related services, supplies, procedures, and care performed as part of this study and not part of your routine medical care will be paid for by the study site, through the study Sponsor.

Who can participate?

Upon reviewing the clinical trial eligibility criteria, speak with your doctor about any questions you may have and clinical trials that may benefit you.

Adults who meet the following criteria may be able to participate in the trial. We cannot guarantee all those who qualify will be selected.

For the relapsed/refractory AML arm of the trial:

  • Men and women aged 18 or older with acute myeloid leukemia that has not responded to treatment or returned following treatment (relapsed or refractory AML per protocol).
  • Participants must have completed prior therapy, including radiation, at least 28 days prior to study treatment.
  • For females of reproductive potential, agreement to use highly effective contraceptive throughout and for six months following last dose study treatment.

What to expect if you are enrolled

Screening and eligibility
(Up to 28 Days Prior to Receiving a Dose of RTX-240)

Participants in the trial will

  • A doctor’s exam
  • Blood tests
  • Pretreatment bone marrow biopsy required
First treatment days

Patients will receive RTX-240 until the time in which the disease progresses or in the event of undesirable toxicities.

During the first week, patients will come in for the first three days, and then weekly for the rest of the cycle.

Follow-up visits

In cycle one, after the first three days, weekly visits are required.

In subsequent cycles, patients come in on day one of dosing and day three, followed by weekly visits.

Dosing days take approximately four to six hours, with subsequent visits to take approximately one hour.

Bone marrow biopsy or aspirate is required at the first two on-treatment disease assessments, and optional at the disease assessments thereafter.

Trial site locations

The Angeles Clinic & Research Institute

Los Angeles, California,

United States, 90025


Contact: Saba Mukarram



Columbia University Medical Center       

New York, New York,

United States, 10032


Contact: Research Nurse Navigator



Massachusetts General Hospital

Boston, Massachusetts,

United States, 02114


Contact: Ryan Sullivan, MD



Oregon Health & Sciences University – Knight Cancer Institute

Portland, Oregon,

United States, 97239


Contact: Knight Cancer Institute Clinical Trials


Sarah Cannon Research Institute
Nashville, Tennessee,

United States, 37203


Contact: Sarah Cannon Research Site



Sylvester Comprehensive Cancer Center/UMHC
Miami, Florida,

United States, 33136


Contact: Jaime Merchan, MD



Virginia Cancer Specialists
Fairfax, Virginia,

United States, 22031


Contact: Alexander Spira, MD, PhD, FACP



Sarah Cannon Research Institute/ Colorado Blood Cancer Institute
Denver, Colorado,

United States, 80218


Contact: Sarah Cannon Research Institute